Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Chief Business Officer | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,568 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 15,000 · Balance 76,568 F1: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 20:33 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025081 · rdgdoc.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,568 F1 · shares: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:15 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030648 · rdgdoc.xml · nonDerivative · entry 2 Disbrow Jarrett · CIK 0001640724 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,568 F2 · shares: Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:15 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 19,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030648 · rdgdoc.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,068 F1 · shares: The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 19:06 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 16,666 | $1.50 | $24,999.00 |
DisclosureSEC source: 0001437749-25-019958 · rdgdoc.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,462 F1 · shares: Purchased pursuant to the Issuer's registered offering more particularly described on the Registration Statement on Form S-1, as amended, filed by the Issuer on June 2, 2025. F2 · balance_after: Total reflects 1-to-20 reverse stock split effected by the Issuer on January 6, 2023. Read SEC document |
| November 06, 2024 Filed Nov 9, 2024 00:49 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0000912282-24-000756 · form4.xml · derivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Shares · 7,000 shares Expires 2034-11-06 F1 · derivative.exercise_date: The options vest as follows: 1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025. Read SEC document |
| August 11, 2023 Filed Aug 16, 2023 00:57 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0000912282-23-000305 · form4.xml · derivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Shares · 7,000 shares Expires 2033-08-12 F1 · derivative.exercise_date: The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 23:48 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 337,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-014530 · ownership.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,475 F1 · price: These are restricted shares which vest on October 24, 2028, subject to earlier vesting in certain situations. F2 · balance_after: Aggregate amount indicated reflects 20-for-1 reverse split and includes additional 5,413 post-split restricted shares previously issued. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:36 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseWarrants · Derivative | 226,105 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001213900-18-002654 · f4030618disbrow_aytubio.xml · derivative · entry 2 Disbrow Jarrett · CIK 0001640724 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,105 Underlying: Common Stock · 226,105 shares Expires 2023-03-06 F2 · price: Warrants were issued as part of units with the shares of common stock. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:36 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 226,105 | $0.45 | $101,747.25 |
DisclosureSEC source: 0001213900-18-002654 · f4030618disbrow_aytubio.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,490 F1 · balance_after: Includes 108,250 restricted shares. Read SEC document |
| November 07, 2017 Filed Nov 10, 2017 00:01 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-17-011708 · f4110717disbrow_aytubio.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,385 F1 · shares: These are restricted shares that vest on November 7, 2027, subject to earlier vesting in certain situations. F1 · price: These are restricted shares that vest on November 7, 2027, subject to earlier vesting in certain situations. F2 · balance_after: Of these shares, 8,250 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
| August 15, 2017 Filed Aug 22, 2017 23:58 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantWarrant to Purchase Common Stock · Derivative | 2,500,000 | $0.18 Strike: $0.18 | $450,000.00 |
DisclosureSEC source: 0001638599-17-000786 · doc4_4899.xml · derivative · entry 2 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500,000 shares Expires 2022-08-15 Read SEC document |
| August 15, 2017 Filed Aug 22, 2017 23:58 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 1,666,667 | $0.15 | $250,000.05 |
DisclosureSEC source: 0001638599-17-000786 · doc4_4899.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,267,671 F1 · balance_after: Of these shares, 165,000 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:20 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 60,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000291 · doc4_4622.xml · derivative · entry 7 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:20 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000291 · doc4_4622.xml · derivative · entry 6 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 33.3% vest on November 11, 2016, 33.3% vest on November 11, 2017 and 33.3% vest on November 11, 2018, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:20 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 60,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000291 · doc4_4622.xml · derivative · entry 5 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:20 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 50,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000291 · doc4_4622.xml · derivative · entry 4 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 33.3% vest on November 11, 2016, 33.3% vest on November 11, 2017 and 33.3% vest on November 11, 2018, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Aug 22, 2017 23:58 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 60,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000786 · doc4_4899.xml · derivative · entry 8 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Aug 22, 2017 23:58 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000786 · doc4_4899.xml · derivative · entry 7 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 33.3% vest on November 11, 2016, 33.3% vest on November 11, 2017 and 33.3% vest on November 11, 2018, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Aug 22, 2017 23:58 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 60,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000786 · doc4_4899.xml · derivative · entry 6 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Aug 22, 2017 23:58 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 50,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000786 · doc4_4899.xml · derivative · entry 5 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 33.3% vest on November 11, 2016, 33.3% vest on November 11, 2017 and 33.3% vest on November 11, 2018, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:43 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionWarrant to Purchase Common Stock · Derivative | 20,834 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000230 · doc4_4571.xml · derivative · entry 3 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,834 shares Expires 2021-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:43 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionWarrant to Purchase Common Stock · Derivative | 166,666 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001638599-17-000230 · doc4_4571.xml · derivative · entry 2 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,666 shares Expires 2021-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:43 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionCommon Stock | 187,500 | $0.75 | $140,625.00 |
DisclosureSEC source: 0001638599-17-000230 · doc4_4571.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Of these shares, 165,000 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:57 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseWarrant to Purchase Common Stock · Derivative | 166,666 | Not disclosed Strike: $1.86 | Not disclosed |
DisclosureSEC source: 0001638599-16-001507 · doc4_4276.xml · derivative · entry 2 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Common Stock · 166,666 shares Expires 2021-11-02 F1 · price: The shares of stock and warrants were purchased at a purchase price per unit of $1.50. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:57 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 166,666 | $1.50 | $249,999.00 |
DisclosureSEC source: 0001638599-16-001507 · doc4_4276.xml · nonDerivative · entry 1 Disbrow Jarrett · CIK 0001640724 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,504 F1 · price: The shares of stock and warrants were purchased at a purchase price per unit of $1.50. F2 · balance_after: Of these shares, 165,000 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.